Updates on the Treatment of Patients With Chronic Myelomonocytic Leukemia

At the 2023 Lymphoma, Leukemia & Myeloma Congress in New York, Eric Padron, MD, Moffit Cancer Center, Tampa, Florida, shares research on the current standard of care in treating chronic myelomonocytic leukemia (CMML). 

Transcript:

Hello everyone. My name is Eric Padron. I'm from the Moffitt Cancer Center in Tampa, and I'm excited to be here at the Leukemia, Lymphoma and Myeloma Conference in New York. Today, I'll be giving a presentation on chronic myelomonocytic leukemia.

I'll be talking about the biology of chronic myelomonocytic leukemia [and] about the underlying genetics and its prevalence. And importantly, we'll be talking about what we think is the optimal management from this disease. And we look at it in 3 categories.

One is accurate diagnoses, and so we're going to go through the World Health Organization criteria as well as the [International Consensus Classification] (ICC) criteria, [and] two is appropriate risk stratification. So, we'll talk about the prognostic models available for CMML, and which models we use in our practice. And last, a personalized therapy. 

We're going to be talking about what we term symptom-directed therapy, which really tailors the treatment that we offer to patients based on what they're feeling, and their symptoms related to their CMML. 

And last, we hope to give a little glimpse into the future about how maybe active surveillance, which is the current standard for clinically asymptomatic patients [and] may not be the right fit for everyone.

Source:

Padron E. Diagnosis and Management of Chronic Myelomonocytic Leukemia. Presented at Lymphoma, Leukemia & Myeloma Congress; October 18-21, 2023. New York, NY